This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Astra Zeneca U.k. Limited. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: The Innovations of Peter Anthony Cittern
Introduction
Peter Anthony Cittern is a notable inventor based in Bristol, GB. He has made significant contributions to the field of chemical compounds, particularly in the development of innovative pharmaceutical solutions. His work has been recognized for its potential impact on health and medicine.
Latest Patents
Peter holds a patent for "Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors." This patent highlights his expertise in creating compounds that can play a crucial role in managing cholesterol levels and improving cardiovascular health.
Career Highlights
Peter is currently employed at AstraZeneca U.K. Limited, a leading global biopharmaceutical company. His role at AstraZeneca allows him to work on cutting-edge research and development projects that aim to address some of the most pressing health challenges today.
Collaborations
Peter has collaborated with esteemed colleagues, including Rebecca Jane Booth and Jeffrey Norman Crabb. These partnerships have fostered a collaborative environment that enhances innovation and drives successful outcomes in their projects.
Conclusion
Peter Anthony Cittern's contributions to the field of chemical compounds and his innovative patent work exemplify his commitment to advancing medical science. His career at AstraZeneca and collaborations with talented professionals further underscore his impact in the industry.